PL2509963T3 - Krystaliczne postaci 3-(2,6-dichloro-3,5-dimetoksyfenylo)-1-{6-[4-(4-etylopiperazyno-1-ylo)-fenylamino]-pirymidyno-4-ylo}-1-metylomocznika i jego soli - Google Patents
Krystaliczne postaci 3-(2,6-dichloro-3,5-dimetoksyfenylo)-1-{6-[4-(4-etylopiperazyno-1-ylo)-fenylamino]-pirymidyno-4-ylo}-1-metylomocznika i jego soliInfo
- Publication number
- PL2509963T3 PL2509963T3 PL10788479T PL10788479T PL2509963T3 PL 2509963 T3 PL2509963 T3 PL 2509963T3 PL 10788479 T PL10788479 T PL 10788479T PL 10788479 T PL10788479 T PL 10788479T PL 2509963 T3 PL2509963 T3 PL 2509963T3
- Authority
- PL
- Poland
- Prior art keywords
- piperazin
- phenylamino
- pyrimidin
- dimethoxy
- dichloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26715509P | 2009-12-07 | 2009-12-07 | |
| EP10788479.3A EP2509963B1 (en) | 2009-12-07 | 2010-12-06 | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof. |
| PCT/US2010/059108 WO2011071821A1 (en) | 2009-12-07 | 2010-12-06 | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2509963T3 true PL2509963T3 (pl) | 2016-05-31 |
Family
ID=43983750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10788479T PL2509963T3 (pl) | 2009-12-07 | 2010-12-06 | Krystaliczne postaci 3-(2,6-dichloro-3,5-dimetoksyfenylo)-1-{6-[4-(4-etylopiperazyno-1-ylo)-fenylamino]-pirymidyno-4-ylo}-1-metylomocznika i jego soli |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9067896B2 (pl) |
| EP (1) | EP2509963B1 (pl) |
| JP (2) | JP5714024B2 (pl) |
| KR (1) | KR101787784B1 (pl) |
| CN (5) | CN111269186A (pl) |
| AR (2) | AR079257A1 (pl) |
| AU (1) | AU2010328391B2 (pl) |
| CA (1) | CA2781431C (pl) |
| CL (1) | CL2012001480A1 (pl) |
| DK (1) | DK2509963T3 (pl) |
| EC (1) | ECSP12012026A (pl) |
| ES (1) | ES2562462T3 (pl) |
| GT (1) | GT201200181A (pl) |
| HK (1) | HK1171016A1 (pl) |
| HR (1) | HRP20160126T1 (pl) |
| HU (1) | HUE026983T2 (pl) |
| IL (1) | IL220012B (pl) |
| JO (1) | JO3061B1 (pl) |
| MA (1) | MA33849B1 (pl) |
| MX (1) | MX2012006562A (pl) |
| MY (1) | MY158333A (pl) |
| NZ (3) | NZ700778A (pl) |
| PE (1) | PE20121499A1 (pl) |
| PH (1) | PH12014502593A1 (pl) |
| PL (1) | PL2509963T3 (pl) |
| RU (1) | RU2572848C2 (pl) |
| SG (1) | SG10201408063SA (pl) |
| SI (1) | SI2509963T1 (pl) |
| TN (1) | TN2012000263A1 (pl) |
| TW (1) | TWI526440B (pl) |
| WO (1) | WO2011071821A1 (pl) |
| ZA (1) | ZA201203612B (pl) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| CN109718239A (zh) * | 2012-03-30 | 2019-05-07 | 诺华股份有限公司 | 用于治疗低磷血性疾病的fgfr抑制剂 |
| BR112014030812B1 (pt) | 2012-06-13 | 2022-11-08 | Incyte Holdings Corporation | Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| KR102350704B1 (ko) | 2013-03-15 | 2022-01-13 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
| EP2968337B1 (en) | 2013-03-15 | 2021-07-21 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| WO2014155268A2 (en) | 2013-03-25 | 2014-10-02 | Novartis Ag | Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity |
| SG10201708520YA (en) | 2013-04-19 | 2017-12-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| JP2016523973A (ja) * | 2013-07-09 | 2016-08-12 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 疾患の処置のためのキナーゼ阻害物質 |
| CN105899490B (zh) * | 2013-10-18 | 2019-07-23 | 卫材R&D管理有限公司 | 嘧啶fgfr4抑制剂 |
| CA2930055C (en) * | 2013-12-13 | 2023-07-04 | Novartis Ag | Pharmaceutical dosage forms comprising protein kinase inhibitor |
| US9951047B2 (en) | 2014-08-18 | 2018-04-24 | Eisai R&D Management Co., Ltd. | Salt of monocyclic pyridine derivative and crystal thereof |
| WO2016055916A1 (en) | 2014-10-06 | 2016-04-14 | Novartis Ag | Therapeutic combination for the treatment of cancer |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2016151501A1 (en) | 2015-03-25 | 2016-09-29 | Novartis Ag | Pharmaceutical combinations |
| US10562888B2 (en) | 2015-04-14 | 2020-02-18 | Eisai R&D Management Co., Ltd. | Crystalline FGFR4 inhibitor compound and uses thereof |
| CN104803925B (zh) * | 2015-04-16 | 2018-01-12 | 温州医科大学 | 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途 |
| WO2016189472A1 (en) | 2015-05-28 | 2016-12-01 | Novartis Ag | Fgfr inhibitor for use in the treatment of the phosphaturic mesenchymal tumor |
| WO2017196854A1 (en) | 2016-05-10 | 2017-11-16 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
| TWI669300B (zh) * | 2016-05-20 | 2019-08-21 | 浙江海正藥業股份有限公司 | 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途 |
| CA3034875A1 (en) * | 2016-08-23 | 2018-03-01 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107176954B (zh) | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
| AU2018361264B2 (en) * | 2017-11-01 | 2021-04-01 | Guangdong Xianqiang Pharmaceutical Co., Ltd | Salt form and crystal form of compound as FGFR4 inhibitor and preparation method thereof |
| BR112020017922A2 (pt) | 2018-03-28 | 2020-12-22 | Eisai R&D Management Co., Ltd. | Agente terapêutico para carcinoma hepatocelular |
| SG11202010882XA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Salts of an fgfr inhibitor |
| KR20210018265A (ko) | 2018-05-04 | 2021-02-17 | 인사이트 코포레이션 | Fgfr 억제제의 고체 형태 및 이의 제조 방법 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2022552324A (ja) | 2019-10-14 | 2022-12-15 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての二環式複素環 |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4069695A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| US11583602B2 (en) | 2021-06-23 | 2023-02-21 | Kimtron, Inc. | System and method for ultra-close proximity irradiation of rotating biomass |
| WO2023174400A1 (zh) * | 2022-03-18 | 2023-09-21 | 上海润石医药科技有限公司 | 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用 |
| CN115785001B (zh) * | 2022-11-23 | 2023-09-15 | 斯坦德药典标准物质研发(湖北)有限公司 | 一种英菲格拉替尼的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| CN101242843A (zh) * | 2005-06-10 | 2008-08-13 | 詹森药业有限公司 | 作为激酶调节剂的氨基嘧啶类化合物 |
| JP5536336B2 (ja) * | 2005-11-08 | 2014-07-02 | チョンウェ ファーマ コーポレイション | α−ヘリックス類似体および癌幹細胞の治療に関する方法 |
| JP5153645B2 (ja) * | 2005-12-21 | 2013-02-27 | ノバルティス アーゲー | Ｆｇｆ阻害剤であるピリミジニルアリールウレア誘導体 |
| BRPI0911491A2 (pt) * | 2008-04-29 | 2016-01-05 | Novartis Ag | métodos de monitoramento da modulação de atividade de quinase de receptor de fator de crescimento de fibroblasto e usos dos ditos métodos. |
| AR079257A1 (es) * | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
-
2010
- 2010-12-03 AR ARP100104472A patent/AR079257A1/es not_active Application Discontinuation
- 2010-12-05 JO JOP/2010/0433A patent/JO3061B1/ar active
- 2010-12-06 WO PCT/US2010/059108 patent/WO2011071821A1/en active Application Filing
- 2010-12-06 US US13/514,308 patent/US9067896B2/en active Active
- 2010-12-06 NZ NZ700778A patent/NZ700778A/en unknown
- 2010-12-06 CA CA2781431A patent/CA2781431C/en active Active
- 2010-12-06 CN CN201911278014.9A patent/CN111269186A/zh active Pending
- 2010-12-06 TW TW099142438A patent/TWI526440B/zh active
- 2010-12-06 CN CN201911273119.5A patent/CN111100078A/zh active Pending
- 2010-12-06 RU RU2012128351/04A patent/RU2572848C2/ru active
- 2010-12-06 ES ES10788479.3T patent/ES2562462T3/es active Active
- 2010-12-06 PE PE2012000772A patent/PE20121499A1/es active IP Right Grant
- 2010-12-06 NZ NZ600070A patent/NZ600070A/en unknown
- 2010-12-06 HU HUE10788479A patent/HUE026983T2/en unknown
- 2010-12-06 PL PL10788479T patent/PL2509963T3/pl unknown
- 2010-12-06 MY MYPI2012002222A patent/MY158333A/en unknown
- 2010-12-06 EP EP10788479.3A patent/EP2509963B1/en active Active
- 2010-12-06 DK DK10788479.3T patent/DK2509963T3/en active
- 2010-12-06 CN CN201510484635.8A patent/CN105061332A/zh active Pending
- 2010-12-06 PH PH12014502593A patent/PH12014502593A1/en unknown
- 2010-12-06 SG SG10201408063SA patent/SG10201408063SA/en unknown
- 2010-12-06 JP JP2012543183A patent/JP5714024B2/ja active Active
- 2010-12-06 NZ NZ624315A patent/NZ624315A/en unknown
- 2010-12-06 AU AU2010328391A patent/AU2010328391B2/en active Active
- 2010-12-06 KR KR1020127017618A patent/KR101787784B1/ko active IP Right Grant
- 2010-12-06 CN CN201911272657.2A patent/CN111100077A/zh active Pending
- 2010-12-06 CN CN2010800550783A patent/CN102639510A/zh active Pending
- 2010-12-06 SI SI201031119A patent/SI2509963T1/sl unknown
- 2010-12-06 MX MX2012006562A patent/MX2012006562A/es active IP Right Grant
-
2012
- 2012-05-17 ZA ZA2012/03612A patent/ZA201203612B/en unknown
- 2012-05-24 IL IL220012A patent/IL220012B/en active IP Right Grant
- 2012-05-25 TN TNP2012000263A patent/TN2012000263A1/en unknown
- 2012-06-06 CL CL2012001480A patent/CL2012001480A1/es unknown
- 2012-06-07 GT GT201200181A patent/GT201200181A/es unknown
- 2012-06-26 MA MA35005A patent/MA33849B1/fr unknown
- 2012-07-05 EC ECSP12012026 patent/ECSP12012026A/es unknown
- 2012-11-19 HK HK12111776.3A patent/HK1171016A1/zh unknown
-
2015
- 2015-01-20 JP JP2015008550A patent/JP6019142B2/ja active Active
-
2016
- 2016-02-04 HR HRP20160126T patent/HRP20160126T1/hr unknown
-
2019
- 2019-01-07 AR ARP190100029A patent/AR114946A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160126T1 (hr) | Kristalinični oblici 3-(2,6-diklor-3,5-dimetoksi-fenil)-1-{6-[4-(4-etilpiperazin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-ureje i njihove soli | |
| HUS000512I2 (hu) | Larotrektinib és/vagy gyógyszerészetileg elfogadható sói, elõnyösen larotrektinib-szulfát, beleértve a larotrektinib-hidrogénszulfátot | |
| HK1199031A1 (en) | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof 2--5--1,2,4- | |
| AP2010005390A0 (en) | Crystal form of phenylamino pyrimidine derivatives. | |
| IL226474A0 (en) | Crystal forms of 5-chloro-n2-@@-isopropoxy-@-methyl-4-piperidine-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]pyrimidine-4,2-diamine | |
| EP1951254A4 (en) | [(2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL) -PHENYL] -5-CHLORO-THIOPHENE-2-YL-SULFONYLUREES [4- (6-HALO-7-SUBSTITUTEES)] AND ASSOCIATED FORMS AND METHODS | |
| IL210176A0 (en) | Substituted pyrimidone derivatives | |
| EP2288324A4 (en) | ABSORBENT HYGIENE WITH DISPENSER | |
| EP2432780A4 (en) | PYRIMIDINE COMPOUND AND ITS USE FOR PEST CONTROL | |
| EP2288323A4 (en) | ABSORBENT PERSONAL HYGIENE ARTICLE HAVING A SIZE ADJUSTMENT PAD | |
| SI2350026T1 (sl) | S sulfoksiminom substituirani derivati anilin pirimidina, kot inhibitorji CDK, njihova izdelava in uporaba kot zdravilo | |
| IL201829A0 (en) | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof | |
| HK1157341A1 (en) | Pyrimidine derivative having cell-protecting activity and use thereof | |
| IL215483A0 (en) | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide | |
| HRP20160578T1 (hr) | Supstituirani furankarboksamidi i njihova upotreba | |
| Alp et al. | Beslöjade avslöjanden: En kvalitativ undersökning med sex slöjbärande muslimska flickor | |
| PL384543A1 (pl) | Sposób oznaczania zawartości kwasu etylenodiaminotetraoctowego i jego soli w węglanie guanidyny i w roztworach technologicznych | |
| FI20075842A0 (fi) | Kiteytetty laktaasi, menetelmä sen valmistamiseksi ja sen käyttö |